EXHIBIT B

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

H me	<u>Quick</u>	Advanc d	Pat Num	Help
	Next List	<u>Bottom</u>	View Cart	

Searching 1976 to present...

Results of Search in 1976 to present db for: ACLM/"disease mediated": 67 patents. Hits 1 through 50 out of 67

Next 50 H	its
Jump To	

Refine Search | aclm/"disease mediated"

- PAT. NO. Title
- 1 6.541.503 T Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
- 2 6,521,632 [T] Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
- 3 6,514,989 T Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
- 4 6,509,377 T Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-.kappa.B
- 5 6,495,565 T .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-.alpha.
- 6 6,492,421 T Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
- 7 6.492.393 T Compounds useful as anti-inflammatory agents
- 8 6,476,023 [T] Aromatic heterocyclic compounds as anti-inflammatory agents
- 9 6,465,507 **T** 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
- 10 6,455,522 T Cyclic sulfonamide derivatives as metalloproteinase inhibitors
- 11 6,441,013 T Sulphonyloxazolamines as therapeutic active ingredients
- 12 6,441,000 T Compounds useful in therapy
- 13 6,429,213 T Cyclic hydroxamic acids as metalloproteinase inhibitors
- 14 6,423,270 T Flow cytometric characterization of amyloid fibrils
- 15 <u>6,414,025</u> **T** <u>Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors NF-.kappa..beta.</u>
- 16 6,407,125 **T** Pharmacological agent and method of treatment
- 17 6,407,065 **T** VLA-4 antagonists
- 18 6,403,632 [T] Lactam metalloprotease inhibitors
- 19 <u>6,399.639</u> **T** Apoptosis inhibitor
- 20 6,384,035 T Heterocycles useful in the treatment of benign prostatic hyperplasia

- 21 6.376,665 T Amide derivatives as inhibitors of matrix metalloproteinases, TNF-.alpha., and aggrecanase
- 22 6,376,505 T 5-HT1A and 5-HT1D.alpha.dalpha antagonists
- 23 6,365,587 T Substituted aryl hydroxamic acids as metalloproteinase inhibitors
- 24 6,365,372 [T] SNF2 related CBP activator protein (SRCAP)
- 25 6,358,945 T Compounds useful as anti-inflammatory agents
- 26 6,344,476 T Inhibition of p38 kinase activity by aryl ureas
- 27 6.344,462 T Heterocyclic compounds as bradykinin antagonists
- 28 6.329.412 T Bisamidine compounds as antiproliferative agents
- 29 <u>6.303,619</u> **T** Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
- 30 6,297,381 T Aromatic heterocyclic compounds as anti-inflammatory agents
- 31 6,288,083 T Chemokine receptor antagonists and methods of use therefor
- 32 6.284,801 T Antirheumatic agents
- 33 6.281.235 Amino acyl amino propargyl diol compounds for treatment of a renin-mediated disease
- 34 <u>6,268,391</u> T Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases
- 35 6,268,379 T Substituted aryl hydroxamic acids as metalloproteinase inhibitors
- 36 6,245,572 **T** Flow cytometric characterization of amyloid fibrils
- 37 6,242,453 T Polycyclo heterocyclic derivatives as antiinflammatory agents
- 38 6,239,168 T Radicicol derivatives
- 39 6,232,338 **T** 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
- 40 <u>6,194,451</u> **T** <u>Matrix metalloproteinase inhibitors</u>
- 41 <u>6,127,393</u> **T** <u>Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method</u>
- 42 6,127,360 T Diamine derivatives and pharmaceutical containing the same
- 43 6,121,319 **T** Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
- 44 6,117,895 T Pharmaceutical preparations for TNF inhibition
- 45 <u>6,087,384</u> **T** Apoptosis inhibitor
- 46 6.083.959 T Quinoline derivatives, processes for their preparation and their use as medicaments
- 47 <u>6.063,772</u> **T** <u>Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes</u>
- 48 <u>6,057,336</u> **T** <u>Lactam metalloprotease inhibitors</u>
- 49 6,039,955 T Nontoxic extract of Larrea tridentata and method of making the same
- 50 6,025,376 T Chiral methylphenyloxazolidinones



2 of 2